New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For JNJ;AGN From The Last 14 Days
Check below for free stories on JNJ;AGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 25, 2014
07:03 EDTJNJVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.
August 22, 2014
19:02 EDTAGNAllergan confirms Pershing written request, board views Valeant offer inadequate
Subscribe for More Information
18:33 EDTAGNPershing Square submits requisite requests from Allergan holders to call meeting
Subscribe for More Information
09:33 EDTAGNValeant to request today special meeting of Allergan holders, CNBC reports
Valeant (VRX) will deliver today a request of 30%-plus of Allergan (AGN) shareholders for a special meeting, CNBC's David Faber reports, citing sources.
06:49 EDTAGNJudge rejects Allergan inquiry to quicken insider trading case, Reuters says
Subscribe for More Information
06:45 EDTAGNJudge refuses to prevent special Allergan shareholder meeting, NY Times says
Subscribe for More Information
August 21, 2014
05:42 EDTJNJIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
17:59 EDTAGNAllergan talks with Salix in defense tactic said to be dormant, Bloomberg says
Subscribe for More Information
17:35 EDTAGNAllergan said to explore options outside of Salix acquisition, Bloomberg says
Subscribe for More Information
10:53 EDTAGNAnalysts say Salix takeover would boost Allergan
Subscribe for More Information
09:46 EDTAGNAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.
07:19 EDTAGNPossible Allergan Salix deal could be 8% accretive in '15-'16, says Wells Fargo
After The Wall Street Journal reported that Allergan (AGN) had approached Salix (SLXP) and other companies about a potential acquisition, Wells Fargo thinks that a largely debt financed purchase of Salix could be 8% accretive for Allergan in 2015-2016, reaching 12% accretion in 2018.
07:07 EDTAGNSome Valeant shareholders express uncertainty over Allergan deal, Reuters says
Subscribe for More Information
07:04 EDTAGNSalix buyout price could be near $192 per share, says William Blair
William Blair believes a combined Allergan (AGN) and Salix (SLXP) would be very attractive. The firm estimates a potential takeover price for Salix towards the high end of its $176-$192 per share range. Salix rose 16% yesterday to $160.80 after Wall Street Journal reported that Allergan approached the company and at least one other about a takeover.
August 19, 2014
17:14 EDTAGNOn The Fly: Closing Wrap
Subscribe for More Information
16:52 EDTAGNAllergan all-cash deal would reduce hostile bid chances, says BMO Capital
Subscribe for More Information
14:40 EDTAGNSterne Agee says Allergan could pay up to $190 for Salix and still be accretive
Subscribe for More Information
13:13 EDTAGNAllergan approached Salix, one other about takeover, WSJ reports
Subscribe for More Information
13:06 EDTAGNSalix jumps 6% to $147.85 after WSJ report of Allergan approach
Subscribe for More Information
13:05 EDTAGNAllergan approached Salix about takeover, WSJ reports
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use